FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US MIAMI, May 21, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the Company’s investigational new drug (IND) application to proceed for […]
The post FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics first appeared on Floridas News.